RxDoctor Payments Data

John Lalonde, MD

Family Medicine · Greensboro, NCNPI 1245274455

Payments from drug & device makers

$14,436in general payments, 2019–2025

Across 775 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • AstraZeneca$2K
  • Viiv Healthcare Company$2K
  • Novo Nordisk$1K
  • Amgen$890
  • Lilly USA, LLC$757
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$14,436100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead107$2,264
AstraZeneca49$1,743
Viiv Healthcare Company104$1,730
Novo Nordisk80$1,030
Amgen61$890
Lilly USA, LLC44$757
AbbVie(2 entities)44$750
Abbott23$536
Merck19$421
Boehringer Ingelheim22$359
Takeda Pharmaceuticals U.S.A., Inc.23$329
Amarin Pharma, Inc.15$315
Pfizer20$311
GSK15$302
Johnson & Johnson(2 entities)15$243
Bayer14$236
Exact Sciences5$217
Astellas Pharma US Inc10$164
Sanofi-aventis U.S. LLC8$147
Otsuka America Pharmaceutical, Inc.6$127
Clarus Therapeutics Inc.9$124
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$119
Kowa Pharmaceuticals America, Inc.8$102
Esperion Therapeutics, Inc.5$80
Xeris Pharmaceuticals, Inc.5$78
Mylan Specialty L.p.2$60
Biohaven Pharmaceuticals, Inc.3$60
Teva Pharmaceuticals USA, Inc.4$58
Biohaven Pharmaceutical Holding Company Ltd.3$56
Dynavax Technologies Corporation3$53
Globus Medical2$52
Antares Pharma, Inc.3$51
Currax Pharmaceuticals LLC3$47
Arbor Pharmaceuticals, Inc.3$45
Harmony Biosciences LLC1$38
Eisai Inc.2$37
Dexcom, Inc.2$36
Redhill Biopharma Inc.2$36
Intra-sana Laboratories1$36
Tolmar, Inc.2$28
Irhythm Technologies, Inc.1$26
Roche Diagnostics Corporation1$26
Ironshore Pharmaceuticals Inc.2$26
IBSA Pharma Inc.1$25
Tris Pharma Inc1$22
Invivyd Inc1$22
Hologic Sales And Service, LLC1$22
Otsuka Pharmaceutical Development & Commercialization, Inc.1$22
Endo Pharmaceuticals Inc.1$21
Idorsia Pharmaceuticals US Inc1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Tactile Systems Technology Inc1$17
Cepheid1$16
Novartis1$16
Inspire Medical Systems, Inc.1$16
Agios Pharmaceuticals, Inc.1$14
Azurity Pharmaceuticals, Inc.1$14
Radius Health, Inc.1$14
Amneal Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,436 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$59,524
Medicare patients
108
Services billed
1,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala15$68,779
JardianceEmpagliflozin74$67,210
MounjaroTirzepatide52$54,153
Soliqua 100-33Insulin Glargine/Lixisenatide40$36,144
OzempicSemaglutide35$34,851
DovatoDolutegravir Sodium/Lamivudine11$32,088
FarxigaDapagliflozin Propanediol32$30,555
EliquisApixaban26$29,450
TrulicityDulaglutide17$26,191
XareltoRivaroxaban15$21,114
LinzessLinaclotide11$11,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,878
Atorvastatin Calcium522$6,914
Tresiba Flextouch U-100Insulin Degludec12$6,676
Rosuvastatin Calcium347$4,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$757$80,34469 claims
GileadBiktarvy$2,264$68,77915 claims
Boehringer IngelheimJardiance$359$67,21074 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$147$36,14440 claims
Novo NordiskOzempic$1,030$34,85135 claims
Viiv Healthcare CompanyDovato$1,730$32,08811 claims
AstraZenecaFarxiga$1,743$30,55532 claims
PfizerEliquis$311$29,45026 claims
Johnson & JohnsonXarelto$243$21,11415 claims
AbbVieLinzess, Synthroid$750$14,60944 claims
GSKTrelegy Ellipta$302$9,87815 claims
Kowa Pharmaceuticals America, Inc.Livalo$102$2,85811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →